3 hours Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Stifel Nicolaus MarketBeat
Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday. They set a “buy” rating and a $47.00 price target on the stock.
Stifel Nicolaus began coverage on Bicara Therapeutics in a research report on Tuesday. They set a “buy” rating and a $47.00 price target on the stock.